Why This Article Was Flagged for Fact-Checking
This article outlining recent analyst ratings and financial news on Globus Medical (NYSE:GMED) was flagged for fact-checking to verify the accuracy of claims about company performance, insider trading activity, and analyst opinions. Investors and readers rely on trustworthy financial information, making it crucial to examine whether the article presents complete, reliable, and unbiased data.
Historical Context
Globus Medical is a prominent medical device company known for its innovative treatments in musculoskeletal health. Analyst ratings and earnings reports are closely watched by market participants due to their impact on stock performance and investor decision-making. In 2025, fluctuations in analyst opinions and stock price targets amid strong quarterly results placed Globus Medical under the spotlight, with further investor interest generated by insider transactions and institutional ownership shifts.
Fact-Checking Key Claims
Claim #1: Zacks Research downgraded Globus Medical from “strong-buy” to “hold.”
The article states, “Zacks Research cut shares of Globus Medical (NYSE:GMED) from a strong-buy rating to a hold rating in a report published on Tuesday, Zacks.com reports.” This is accurate. On December 11, 2025, Zacks.com officially reported this downgrade, reflecting a shift in analyst sentiment backed by Zacks’s own research data (marketbeat.com).
Claim #2: Morgan Stanley increased its price target for Globus Medical to $100 and maintained an “overweight” rating.
The article claims, “Morgan Stanley upped their price target on shares of Globus Medical from $70.00 to $100.00 and gave the company an ‘overweight’ rating in a report on Tuesday, December 2nd.” This statement is accurate. On December 2, 2025, Morgan Stanley confirmed an updated price target of $100 and reiterated their “overweight” rating (benzinga.com).
Claim #3: Globus Medical beat quarterly earnings estimates, reporting $1.18 EPS for the quarter ending November 6, 2025.
The article asserts, “The medical device company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39.” This is accurate. Financial filings and reputable investment news sources have confirmed that Globus Medical posted $1.18 earnings per share for its most recent quarter, surpassing the analyst consensus of $0.79 (ainvest.com).
Claim #4: CFO Kyle Kline sold 18,542 shares of Globus Medical stock on December 1, 2025.
The article reports, “CFO Kyle Kline sold 18,542 shares of the firm’s stock in a transaction on Monday, December 1st.” This transaction has been verified as accurate. Public SEC filings and financial news confirm that this sale took place as described, as part of regular insider trading disclosures (ainvest.com).
Conclusion
Based on current, reliable research and the latest analyst and financial disclosures, the key claims in this article concerning Globus Medical’s analyst ratings, earnings reports, price targets, and insider activity are accurate and reflect the true state of the company’s recent market developments. The reporting is aligned with publicly documented sources and does not exhibit bias, omission, or misleading context. Readers can rely on the facts as presented in this coverage for their decision-making.
Take Action Now
Stay informed and fight misinformation by joining a community committed to the truth. Download the DBUNK App today to review and request fact-checks for the news that matters to you.
Original Article Link
Read the original article: Visit the Article
